The potential of the Enriched Enrollment Randomized Withdrawal (EERW) paradigm for proof of concept studies of novel agents for the treatment of neuropathic pain (NP)
David Hewitt(Glasgow Royal Infirmary), David Kudrow(California Medical Clinic for Headache), Paul J. Markovitz(Center for Anxiety and Depression), James A. Bolognese(Cytel (United States)), Arnold R. Gammaitoni(Merck & Co., Inc., Rahway, NJ, USA (United States)), Tony W. Ho(Johns Hopkins University), David Michelson(Merck & Co., Inc., Rahway, NJ, USA (United States)), Achilles Alon(Merck & Co., Inc., Rahway, NJ, USA (United States)), H. Wang(Merck & Co., Inc., Rahway, NJ, USA (United States)), M. Backonja(Merck & Co., Inc., Rahway, NJ, USA (United States)), Bradley S. Galer(Rapt Therapeutics (United States))
Cited by 2
Related Papers
Advances in Neuropathic Pain
|Archives of Neurology|2003|1.2k
Sources of variance in 24-hour dietary recall data: implications for nutrition study design and interpretation
|American Journal of Clinical Nutrition|1979|997
MALIGNANT DISEASE IN CHILDHOOD AND DIAGNOSTIC IRRADIATION IN UTERO
|The Lancet|1956|569